z-logo
open-access-imgOpen Access
Pharmacological Inhibition of the ClpXP Protease Increases Bacterial Susceptibility to Host Cathelicidin Antimicrobial Peptides and Cell Envelope-Active Antibiotics
Author(s) -
Shauna M. McGillivray,
Dan N. Tran,
Nitya S. Ramadoss,
John N. Alumasa,
Cheryl Okumura,
George Sakoulas,
Micah Vaughn,
Dawn X. Zhang,
Kenneth C. Keiler,
Victor Nizet
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.05131-11
Subject(s) - cathelicidin , protease , antimicrobial , microbiology and biotechnology , antimicrobial peptides , biology , antibiotics , daptomycin , staphylococcus aureus , bacteria , biochemistry , enzyme , vancomycin , genetics
The ClpXP protease is a critical bacterial intracellular protease that regulates protein turnover in many bacterial species. Here we identified a pharmacological inhibitor of the ClpXP protease, F2, and evaluated its action in Bacillus anthracis and Staphylococcus aureus. We found that F2 exhibited synergistic antimicrobial activity with cathelicidin antimicrobial peptides and antibiotics that target the cell well and/or cell membrane, such as penicillin and daptomycin, in B. anthracis and drug-resistant strains of S. aureus. ClpXP inhibition represents a novel therapeutic strategy to simultaneously sensitize pathogenic bacteria to host defenses and pharmaceutical antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom